Wei Ling-Xia, Ding Mao-Peng, Wang Zhi-Wang, Liu Xue-Feng, Pang Ya-Rong, Guo Mei
Gansu College of Traditional Chinese Medicine, Lanzhou 730000, China.
Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2020 Nov;36(6):582-586. doi: 10.12047/j.cjap.6109.2020.122.
To investigate the prevention and treatment effect of (BYG) on ethanol-induced hepatic fibrosis (EHF) rats. SD rats were randomly divided into blank control group, model group, BYG group, colchicine group and BYG low and BYG high dose groups (=8). The EHF rat model was established by intragastric edible ethanol with a gradually increased dose. Briefly, the rats of model group, colchicine group and BYG low and high dose groups were given gavage of 5 g/(kg·d) ethanol at week 1～4, 7 g/(kg·d) ethanol at week 5～8, 9 g/(kg·d) ethanol at week 9～12 and 9.5 g/(kg·d) ethanol at week 13～24. And the other two groups were treated with equal volume water. At the same time, the corresponding drugs were administrated daily: BYG group was treated with 5.55 g/kg, colchicine group was treated with colchicine 0.1 mg/kg, BYG low-dose and high-group were treated with 1.85 and 5.55 g/kg respectively. The blank control group and model control group were given the same amount of purified water. On the 169th day of the experiment, the effects of BYG on the macroscopic changes of rat liver organs, the water content of liver tissue and the pathological changes of fibrosis, the content of hydroxy proline (Hyp) in liver tissue and the expression levels of α-SMA and CREB were observed. BYG at the doses of 1.85 and 5.55 g/kg could significantly improve the macroscopic changes of liver and pathological changes of liver tissue fibrosis in rats with EHF, reduce the contents of water and Hyp in liver tissue, and down-regulate the expressions of α-SMA and CREB. BYG has obvious effect on inhibiting EHF and one of its mechanisms is down-regulate the content of CREB.
探讨（药物名称未给出，推测为某种中药复方制剂）对乙醇诱导的肝纤维化（EHF）大鼠的防治作用。将SD大鼠随机分为空白对照组、模型组、药物组、秋水仙碱组以及药物低剂量和高剂量组（每组n = 8）。采用逐渐增加剂量的食用乙醇灌胃法建立EHF大鼠模型。简要方法为，模型组、秋水仙碱组以及药物低剂量和高剂量组的大鼠在第1～4周给予5 g/(kg·d)乙醇灌胃，第5～8周给予7 g/(kg·d)乙醇灌胃，第9～12周给予9 g/(kg·d)乙醇灌胃，第13～24周给予9.5 g/(kg·d)乙醇灌胃。另外两组给予等体积的水。同时，每日给予相应药物：药物组给予5.55 g/kg，秋水仙碱组给予秋水仙碱0.1 mg/kg，药物低剂量组和高剂量组分别给予1.85 g/kg和5.55 g/kg。空白对照组和模型对照组给予等量的纯化水。在实验第169天，观察药物对大鼠肝脏器官宏观变化、肝组织含水量及纤维化病理变化、肝组织中羟脯氨酸（Hyp）含量以及α-SMA和CREB表达水平的影响。1.85 g/kg和5.55 g/kg剂量的药物可显著改善EHF大鼠肝脏的宏观变化及肝组织纤维化的病理变化，降低肝组织中的含水量和Hyp含量，并下调α-SMA和CREB的表达。药物对抑制EHF有明显作用，其机制之一是下调CREB的含量。
